SEPN Stock Summary and Trading Ideas (Septerna | NASDAQ:SEPN)

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna trades on the NASDAQ stock market under the symbol SEPN.

As of March 13, 2026, SEPN stock price declined to $25.14 with 271,735 million shares trading.

SEPN has a beta of 1.64, meaning it tends to be more sensitive to market movements. SEPN has a correlation of 0.16 to the broad based SPY ETF.

SEPN has a market cap of $1.13 billion. This is considered a Small Cap stock.

Last quarter Septerna reported $24 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.02.

The top ETF exchange traded funds that SEPN belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

SEPN has outperformed the market in the last year with a return of +293.4%, while the SPY ETF gained +21.4%. In the last 3 month period, SEPN beat the market returning -1.2%, while SPY returned -2.6%. However, in the most recent 2 weeks SEPN has underperformed the stock market by returning -13.4%, while SPY returned -3.5%.

SEPN support price is $25.00 and resistance is $27.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEPN shares will trade within this expected range on the day.